GreenlandS. An introduction to instrumental variables for epidemiologists. Int J Epidemiol, 2000; 29:722–729.
2.
KatanMB. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet, 1986; 1:507–508.
3.
KatanMB. Commentary. Mendelian randomization, 18 years on. Int J Epidemiol, 2004; 33:10–11.
4.
Davey SmithG, EbrahimS. “Mendelian randomization”: Can genetic epidemiology contribute to understanding environmental determinants of disease?Int J Epidemiol, 2003; 32:1–22.
5.
BochudM. On the use of Mendelian randomization to infer causality in observational epidemiology. Eur Heart J, 2008; 29:2456–2457.
6.
SheehanNA, DidelezV, BurtonPR, TobinMD. Mendelian randomization and causal inference in observational epidemiology. PLoS Med, 2008; 5:e177.
7.
HernanMA, RobinsJM. Instruments for causal inference. An epidemiologist's dream?Epidemiology, 2006; 17:360–372.
8.
GlynnRJ. Promises and limitations of Mendelian randomization for evaluation of biomarkers. Clin Chem, 2010; 56:388–390.
9.
OgbuanuIU, ZhangH, KarmusW. Can we apply Mendelian randomization methodology without considering epigenetic effects?Emerg Themes Epidemiol, 2009; 6:3.
10.
WaldDS, LawM, MorrisJK. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ, 2002; 325:1202–1209.
11.
RidkerPM, PareG, ParkerAN, ZeeRYL, MiletichJP, ChasmanDI. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet, 2009; 2:26–33.
12.
HlatkyMA, GreenlandP, ArnettDK, BallantyneCM, CriquiMH, ElkindMSVet al. on behalf of the American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk. A scientific statement from the American Heart Association. Circulation, 2009; 119:2408–2416.
13.
LibbyP, RidkerPM, MaseriA. Inflammation and atherosclerosis. Circulation, 2002; 105:1135–1143.
14.
The Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. Lancet, 2010; 375:132–140.
15.
RidkerPM, RifaiN, PfefferMA, SacksFM, MoyeLA, GoldmanS, FlakerGC, BraunwaldE. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 1998; 98:839–844.
16.
AlbertMA, DanielsonE, RifaiN, RidkerPM. for the PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study. JAMA, 2001; 286:64–70.
17.
RidkerPM, RifaiN, ClearfieldM, DownsJR, WeisSE, MilesJS, GottoAMJr.Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. NEJM, 2001; 344:1959–1965.
18.
RidkerPM, DanielsonE, FonsecaFA, GenestJ, GottoAMJr., KasteleinJJ, KoenigW, LibbyP, LorenzattiAJ, MacFadyenJG, NordestgaardBG, ShepherdJ, WillersonJT, GlynnRJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. NEJM, 2008; 359:2195–2207.
19.
RidkerPM, CannonCP, MorrowD, RifaiN, RoseLM, McCabeCH, PfefferMA, BraunwaldE. C-reactive protein levels and outcomes after statin therapy. NEJM, 2005; 352:20–28.
MorrowDA, de LemosJA, SabatineMS, WiviottSD, BlazingMA, ShuiA, RifaiN, CaliffRM, BraunwaldE. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation, 2006; 114:281–288.
22.
RidkerPM, DanielsonE, FonsecaFA, GenestJ, GottoAMJr., KasteleinJJ, KoenigW, LibbyP, LorenzattiAJ, MacfadyenJG, NordestgaardBG, ShepherdJ, WillersonJT, GlynnRJ. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet, 2009; 373:1175–1182.
23.
PearsonTA, MensahGA, AlexanderRW, AndersonJL, CannonRO3rd, CriquiM, FadlYY, FortmannSP, HongY, MyersGL, RifaiN, SmithSCJr., TaubertK, TracyRP, VinicorF. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 2003; 107:499–511.
24.
NACB LMPG Committee Members. MyersGL, ChristensonRHM, CushmanM, BallantyneCM, CoperGR, PfeifferCE, GrundySM, LabartheDR, LevyD, RifaiN, WilsonPWF. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem, 2009; 55:378–384.
GenestJ, McPhersonR, FrohlichJ, AndersonT, CampbellN, CarpentierA, CoutureP, DufourR, FodorG, FrancisGA, GroverS, GuptaM, HegeleRA, LauDC, LeiterL, LewisGF, LonnE, ManciniGB, NgD, PearsonGJ, SnidermanA, StoneJA, UrE. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations. Can J Cardiol, 2009; 25:567–579.
